Detalhe da pesquisa
1.
New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options.
Medicina (Kaunas)
; 57(11)2021 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34833399
2.
20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.
Am J Hematol
; 94(3): 286-290, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30516867
3.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Hematol Oncol
; 2018 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29624703
4.
Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.
Am J Hematol
; 93(12): 1474-1484, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30157297
5.
SFLT-1 levels in COVID-19 patients: Association with outcome and thrombosis.
Am J Hematol
; 96(2): E41-E43, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33108012
6.
The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes.
Am J Hematol
; 93(7): E164-E167, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659079
7.
Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020.
Front Oncol
; 13: 1182971, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37534259
8.
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Blood Adv
; 6(1): 327-338, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34644385
9.
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
Leuk Lymphoma
; 62(4): 828-836, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33274677
10.
Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.
Blood Cancer J
; 9(2): 12, 2019 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30683837
11.
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.
Mayo Clin Proc
; 94(4): 599-610, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30824279
12.
Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment.
Leuk Lymphoma
; 64(10): 1723-1726, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37440354
13.
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâ.
Semin Hematol
; 55(4): 248-255, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30502854
14.
Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies.
Leukemia
; 33(10): 2522-2553, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31040370
15.
Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.
Blood Cancer J
; 8(12): 118, 2018 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30455425
16.
Genetic predictors of response to specific drugs in primary myelofibrosis.
Blood Cancer J
; 8(12): 120, 2018 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30455475
17.
Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels.
Blood Adv
; 2(15): 1980-1984, 2018 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30097464